二肽基肽酶4抑制剂的临床应用及前景  

Clinical Application and Prospect of DPP-4 Inhibitors

作　　者：胡璟[1] 肖常青[2] 庞翠军[2] 

机构地区：[1]桂林医学院附属医院内分泌科,广西桂林541001 [2]广西医科大学第一附属医院内分泌代谢病科,南宁530021

出　　处：《医学综述》2015年第20期3729-3732,共4页Medical Recapitulate

基　　金：广西高校科学技术研究项目(KY2015LX262)

摘　　要：二肽基肽酶4(DPP-4)抑制剂通过延缓胰升糖素样多肽1(GLP-1)、糖依赖性胰岛素释放肽(GIP)降解而延长生理性GLP-1作用时间达到降低血糖的作用,除此之以外它的众多胰腺外作用逐渐被发现。DPP-4抑制剂可以安全的单独使用及和与多种口服降糖药物、及胰岛素联合使用,不影响体质量,不增加低血糖发生风险,性价比较高,在临床上逐渐广泛应用广泛,有良好的应用前景,已成为治疗2型糖尿病的又一个有力武器。Dipeptidylpeptidase 4 （DPP-4） inhibitors by slowing down glucagon-like peptide-1 （ GLP-1 ）, glucose dependent insulinotropic peptide degradation and prolonging the acting time of physiologic GLP-1 to lower blood sugar action, besides its multiple functions besides pancreas function were gradually found. DPP- 4 inhibitors can be safely used alone and in combination with a variety of oral hypoglycemic drugs and insu- lin, which does not affect the body weight, does not increase the risk of hypoglycaemia, and has high cost per- formance ratio, and is being widely used in clinical gradually, with good application prospect, which has become another powerful weapon for the treatment of type 2 diabetes mellitus.

关 键 词：2型糖尿病 二肽基肽酶 4抑制剂 作用机制 临床应用 

分 类 号：R587.1[医药卫生—内分泌]